CH642847A5 - Pharmaceutical composition for the treatment of heart disease - Google Patents
Pharmaceutical composition for the treatment of heart disease Download PDFInfo
- Publication number
- CH642847A5 CH642847A5 CH1119878A CH1119878A CH642847A5 CH 642847 A5 CH642847 A5 CH 642847A5 CH 1119878 A CH1119878 A CH 1119878A CH 1119878 A CH1119878 A CH 1119878A CH 642847 A5 CH642847 A5 CH 642847A5
- Authority
- CH
- Switzerland
- Prior art keywords
- carnitine
- acetyl
- treatment
- heart
- pharmaceutical composition
- Prior art date
Links
- 208000019622 heart disease Diseases 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 229960004203 carnitine Drugs 0.000 description 16
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 6
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000001426 cardiotropic effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000002763 arrhythmic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000009090 positive inotropic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- -1 aliphatic saturated fatty acid Chemical class 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT51663/77A IT1143611B (it) | 1977-11-03 | 1977-11-03 | Applicazione della acetil-carnitina nella terapia delle affezioni cardiache di/tipo anossico,ischemico,cardiotossico e nelle sindromi aritmiche |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH642847A5 true CH642847A5 (en) | 1984-05-15 |
Family
ID=11275497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1119878A CH642847A5 (en) | 1977-11-03 | 1978-10-31 | Pharmaceutical composition for the treatment of heart disease |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS5476830A (enrdf_load_stackoverflow) |
| AU (1) | AU524988B2 (enrdf_load_stackoverflow) |
| BE (1) | BE871753A (enrdf_load_stackoverflow) |
| CH (1) | CH642847A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2846335A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2407717A1 (enrdf_load_stackoverflow) |
| IT (1) | IT1143611B (enrdf_load_stackoverflow) |
| NL (1) | NL7810818A (enrdf_load_stackoverflow) |
| ZA (1) | ZA785998B (enrdf_load_stackoverflow) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2903579A1 (de) * | 1978-02-03 | 1979-08-09 | Sigma Tau Ind Farmaceuti | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel |
| IT1156741B (it) * | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| IT1206954B (it) * | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche |
| IT1116037B (it) * | 1979-04-23 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico |
| IT1150396B (it) * | 1982-12-09 | 1986-12-10 | Sigma Tau Ind Farmaceuti | Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari |
| JP2006347935A (ja) * | 2005-06-15 | 2006-12-28 | Masanori Ogata | 炎症性サイトカインの産生が関与する疾患の予防及び／又は治療のための医薬 |
| JP5214249B2 (ja) | 2006-11-09 | 2013-06-19 | 三菱レイヨン株式会社 | ベタインの製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3624887A (en) * | 1970-03-02 | 1971-12-07 | Bunker Ramo | Pin and socket removal tool |
| US3968241A (en) * | 1972-11-06 | 1976-07-06 | Defelice Stephen L | Method of treating cardiac arrhythmias and of improving myocardial contractility and systolic rhythm with carnitive or a pharmaceutically acceptable salt thereof |
| US3830931A (en) * | 1972-11-06 | 1974-08-20 | Felice S De | Carnitine and its use in the treatment of arrhythmia and impaired cardiac function |
| JPS531812B2 (enrdf_load_stackoverflow) * | 1972-12-07 | 1978-01-23 | ||
| JPS5058213A (enrdf_load_stackoverflow) * | 1973-09-26 | 1975-05-21 |
-
1977
- 1977-11-03 IT IT51663/77A patent/IT1143611B/it active
-
1978
- 1978-10-24 ZA ZA785998A patent/ZA785998B/xx unknown
- 1978-10-25 DE DE19782846335 patent/DE2846335A1/de not_active Withdrawn
- 1978-10-30 FR FR7830780A patent/FR2407717A1/fr active Granted
- 1978-10-31 NL NL7810818A patent/NL7810818A/xx not_active Application Discontinuation
- 1978-10-31 CH CH1119878A patent/CH642847A5/it not_active IP Right Cessation
- 1978-11-02 JP JP13564378A patent/JPS5476830A/ja active Granted
- 1978-11-03 AU AU41316/78A patent/AU524988B2/en not_active Expired
- 1978-11-03 BE BE191526A patent/BE871753A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IT1143611B (it) | 1986-10-22 |
| NL7810818A (nl) | 1979-05-07 |
| FR2407717B1 (enrdf_load_stackoverflow) | 1980-10-03 |
| BE871753A (fr) | 1979-03-01 |
| ZA785998B (en) | 1980-06-25 |
| AU4131678A (en) | 1979-05-17 |
| AU524988B2 (en) | 1982-10-14 |
| JPS649288B2 (enrdf_load_stackoverflow) | 1989-02-16 |
| JPS5476830A (en) | 1979-06-19 |
| DE2846335A1 (de) | 1979-05-10 |
| FR2407717A1 (fr) | 1979-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH636268A5 (it) | Composizioni farmaceutiche, contenenti derivati della d,1-carnitina attivi nella terepia delle affezioni cardiache. | |
| CH641673A5 (it) | Composizione farmaceutica comprendente una acil-carnitina per il trattamento del rallentato metabolismo cerebrale. | |
| CH655005A5 (it) | Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. | |
| JP3192141B2 (ja) | 抗うつ剤 | |
| BRPI0611322A2 (pt) | métodos e composicões para controlar distúrbios psicóticos | |
| Brogden et al. | Levodopa: A review of its pharmacological properties and therapeutic uses with particular reference to Parkinsonism | |
| CH640413A5 (it) | Preparato farmaceutico per il trattamento di iperlipoproteinemie. | |
| KR940008694A (ko) | 비인슐린 의존성 당뇨병 환자의 장기간 치료를 위한 l-카르니틴 및 아실 l-카르니틴을 함유한 의약 조성물 및 그 용도 | |
| JPH04502161A (ja) | 緑内障の治療処置におけるアセチルｄ―カルニチンの用途 | |
| CN105294676B (zh) | 一种小檗碱复盐及其制备方法和用途 | |
| CH642847A5 (en) | Pharmaceutical composition for the treatment of heart disease | |
| PT796103E (pt) | Utilizacao de incenso para tratamento da doenca de alzheimer | |
| WO2014180239A1 (zh) | 一种治疗重症高原病的药物组合物 | |
| Francisco et al. | Structure-activity relationship of dibenzylideneacetone analogs against the neglected disease pathogen, Trypanosoma brucei | |
| AQUILONIUS et al. | Choline therapy in Huntington chorea | |
| US20040024056A1 (en) | Dihydrofuran cyclic tanshinones used in treating hyperammonemia and hepatic encephalopathy | |
| BRPI0722181A2 (pt) | "medicamento antimelancólico preparado com materiais à base de camp de jujuba" | |
| CN101564378B (zh) | 左卡尼汀口服溶液及其制备方法 | |
| IE51711B1 (en) | Carnitine derivatives | |
| US20100120907A1 (en) | Derivatives of amyris alcohols and eudesmol for treating cold sores and herpes | |
| US12226387B2 (en) | Compounds for use in cancer cachexia | |
| CN1923227B (zh) | 一种用于治疗缺血性心脑血管疾病的中药制剂 | |
| Lutmer et al. | Myocardial and serum lactate changes during isoproterenol-induced infarction | |
| KR20020015609A (ko) | 세로토닌 ｎ-아세틸트란스퍼라제의 활성 억제제 | |
| US3462534A (en) | Production of an antidepressant effect with esters of gallic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |